395 related articles for article (PubMed ID: 27559961)
21. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
22. Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study.
Tenforde MW; Yadav A; Dowdy DW; Gupte N; Shivakoti R; Yang WT; Mwelase N; Kanyama C; Pillay S; Samaneka W; Santos B; Poongulali S; Tripathy S; Riviere C; Berendes S; Lama JR; Cardoso SW; Sugandhavesa P; Christian P; Semba RD; Campbell TB; Gupta A;
J Acquir Immune Defic Syndr; 2017 Jul; 75(3):e71-e79. PubMed ID: 28169875
[TBL] [Abstract][Full Text] [Related]
23. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
Chirehwa MT; McIlleron H; Wiesner L; Affolabi D; Bah-Sow O; Merle C; Denti P;
J Antimicrob Chemother; 2019 Jan; 74(1):139-148. PubMed ID: 30239829
[TBL] [Abstract][Full Text] [Related]
24. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania.
Mugusi S; Ngaimisi E; Janabi M; Minzi O; Bakari M; Riedel KD; Burhenne J; Lindquist L; Mugusi F; Sandstrom E; Aklillu E
PLoS One; 2012; 7(7):e40180. PubMed ID: 22808112
[TBL] [Abstract][Full Text] [Related]
25. CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.
Manosuthi W; Sukasem C; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2014; 58(4):2268-73. PubMed ID: 24492364
[TBL] [Abstract][Full Text] [Related]
26. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Friedland G; Khoo S; Jack C; Lalloo U
J Antimicrob Chemother; 2006 Dec; 58(6):1299-302. PubMed ID: 17032686
[TBL] [Abstract][Full Text] [Related]
27. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy?
Orrell C; Cohen K; Conradie F; Zeinecker J; Ive P; Sanne I; Wood R
Antivir Ther; 2011; 16(4):527-34. PubMed ID: 21685540
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D deficiency in Malawian adults with pulmonary tuberculosis: risk factors and treatment outcomes.
Sloan DJ; Mwandumba HC; Kamdolozi M; Shani D; Chisale B; Dutton J; Khoo SH; Allain TJ; Davies GR
Int J Tuberc Lung Dis; 2015 Aug; 19(8):904-11. PubMed ID: 26162355
[TBL] [Abstract][Full Text] [Related]
29. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study.
Sinha S; Raghunandan P; Chandrashekhar R; Sharma SK; Kumar S; Dhooria S; Ekka M; Velpandian T; Ranjan S; Ahmad H; Samantaray JC; Venkatesh S; Rewari BB; Khan NH; Pandey RM
BMC Infect Dis; 2013 Oct; 13():482. PubMed ID: 24134449
[TBL] [Abstract][Full Text] [Related]
30. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs.
Allavena C; Delpierre C; Cuzin L; Rey D; Viget N; Bernard J; Guillot P; Duvivier C; Billaud E; Raffi F
J Antimicrob Chemother; 2012 Sep; 67(9):2222-30. PubMed ID: 22589455
[TBL] [Abstract][Full Text] [Related]
31. Effects of vitamin D supplementation on the bone specific biomarkers in HIV infected individuals under treatment with efavirenz.
Etminani-Esfahani M; Khalili H; Jafari S; Abdollahi A; Dashti-Khavidaki S
BMC Res Notes; 2012 Apr; 5():204. PubMed ID: 22537736
[TBL] [Abstract][Full Text] [Related]
32. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis.
Terrier B; Carrat F; Geri G; Pol S; Piroth L; Halfon P; Poynard T; Souberbielle JC; Cacoub P
J Hepatol; 2011 Oct; 55(4):756-61. PubMed ID: 21334402
[TBL] [Abstract][Full Text] [Related]
33. Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome.
Conesa-Botella A; Meintjes G; Coussens AK; van der Plas H; Goliath R; Schutz C; Moreno-Reyes R; Mehta M; Martineau AR; Wilkinson RJ; Colebunders R; Wilkinson KA
Clin Infect Dis; 2012 Oct; 55(7):1004-11. PubMed ID: 22715179
[TBL] [Abstract][Full Text] [Related]
34. Vitamin D as Modulator of Drug Concentrations: A Study on Two Italian Cohorts of People Living with HIV Administered with Efavirenz.
Cusato J; Tempestilli M; Calcagno A; Vergori A; Piselli P; Antonucci M; Avataneo V; Palermiti A; Notari S; Antinori A; Di Perri G; Agrati C; D'Avolio A
Nutrients; 2021 Oct; 13(10):. PubMed ID: 34684572
[TBL] [Abstract][Full Text] [Related]
35. T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens.
da Silva TP; Giacoia-Gripp CB; Schmaltz CA; Sant Anna FM; Rolla V; Morgado MG
PLoS One; 2013; 8(6):e66095. PubMed ID: 23840403
[TBL] [Abstract][Full Text] [Related]
36. Severe hypovitaminosis D in active tuberculosis patients and its predictors.
Wang Q; Liu Y; Ma Y; Han L; Dou M; Zou Y; Sun L; Tian H; Li T; Jiang G; Du B; Kou T; Song J; Kok FJ; Schouten EG
Clin Nutr; 2018 Jun; 37(3):1034-1040. PubMed ID: 28514999
[TBL] [Abstract][Full Text] [Related]
37. Differences in response to antiretroviral therapy in HIV-positive patients being treated for tuberculosis in Eastern Europe, Western Europe and Latin America.
Caro-Vega Y; Schultze A; W Efsen AM; Post FA; Panteleev A; Skrahin A; Miro JM; Girardi E; Podlekareva DN; Lundgren JD; Sierra-Madero J; Toibaro J; Andrade-Villanueva J; Tetradov S; Fehr J; Caylà J; Losso MH; Miller RF; Mocroft A; Kirk O; Crabtree-Ramírez B
BMC Infect Dis; 2018 Apr; 18(1):191. PubMed ID: 29685113
[TBL] [Abstract][Full Text] [Related]
38. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
39. Higher vitamin D levels in HIV-infected out-patients on treatment with boosted protease inhibitor monotherapy.
Cervero M; Agud JL; Torres R; García-Lacalle C; Alcázar V; Jusdado JJ; Moreno S
HIV Med; 2013 Oct; 14(9):556-62. PubMed ID: 23738846
[TBL] [Abstract][Full Text] [Related]
40. 25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings.
Havers F; Smeaton L; Gupte N; Detrick B; Bollinger RC; Hakim J; Kumarasamy N; Andrade A; Christian P; Lama JR; Campbell TB; Gupta A; ;
J Infect Dis; 2014 Jul; 210(2):244-53. PubMed ID: 24799602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
